XML 36 R18.htm IDEA: XBRL DOCUMENT v3.22.1
OTHER ASSETS
 12 Months Ended
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
OTHER ASSETS

NOTE 12– OTHER ASSETS

 

On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions:

 

Price at valuation  $ 0.19 – 0.26   
Exercise price  $0.19 
Risk free interest    0.66 - 0.73 %
Expected term (in years)   10 
Volatility    140.6 - 143.9 %

 

The Company considers this to be level 3 inputs and is valued at each reporting period. The fair value of these warrants for the year ended December 31, 2021 was $18. There was a net $6 change in fair value during the year ended December 31, 2021.